학술논문
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
Document Type
Article
Author
Source
In: Clinical Colorectal Cancer . (Clinical Colorectal Cancer, December 2021, 20(4):314-317)
Subject
Language
English
ISSN
19380674
15330028
15330028